Your browser doesn't support javascript.
loading
Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
Nguyen, Ferro; Alferiev, Ivan; Guan, Peng; Guerrero, David T; Kolla, Venkatadri; Moorthy, Ganesh S; Chorny, Michael; Brodeur, Garrett M.
Affiliation
  • Nguyen F; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Alferiev I; Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Guan P; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Guerrero DT; Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Kolla V; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Moorthy GS; Department of Anesthesiology and Critical Care, University of Pennsylvania/Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Chorny M; Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Brodeur GM; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Brodeur@email.chop.edu.
Clin Cancer Res ; 24(11): 2585-2593, 2018 06 01.
Article de En | MEDLINE | ID: mdl-29514842
ABSTRACT

Purpose:

Currently, <50% of high-risk pediatric solid tumors like neuroblastoma can be cured, and many survivors experience serious or life-threatening toxicities, so more effective, less toxic therapy is needed. One approach is to target drugs to tumors using nanoparticles, which take advantage of the enhanced permeability of tumor vasculature.Experimental

Design:

SN38, the active metabolite of irinotecan (CPT-11), is a potent therapeutic agent that is readily encapsulated in polymeric nanoparticles. Tocopherol oxyacetate (TOA) is a hydrophobic mitocan that was linked to SN38 to significantly increase hydrophobicity and enhance nanoparticle retention. We treated neuroblastomas with SN38-TOA nanoparticles and compared the efficacy with the parent prodrug CPT-11 using a mouse xenograft model.

Results:

Nanoparticle treatment induced prolonged event-free survival (EFS) in most mice, compared with CPT-11. This was shown for both SH-SY5Y and IMR-32 neuroblastoma xenografts. Enhanced efficacy was likely due to increased and sustained drug levels of SN38 in the tumor compared with conventional CPT-11 delivery. Interestingly, when recurrent CPT-11-treated tumors were re-treated with SN38-TOA nanoparticles, the tumors transformed from undifferentiated neuroblastomas to maturing ganglioneuroblastomas. Furthermore, these tumors were infiltrated with Schwann cells of mouse origin, which may have contributed to the differentiated histology.

Conclusions:

Nanoparticle delivery of SN38-TOA produced increased drug delivery and prolonged EFS compared to conventional delivery of CPT-11. Also, lower total dose and drug entrapment in nanoparticles during circulation should decrease toxicity. We propose that nanoparticle-based delivery of a rationally designed prodrug is an attractive approach to enhance chemotherapeutic efficacy in pediatric and adult tumors. Clin Cancer Res; 24(11); 2585-93. ©2018 AACR.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Promédicaments / Systèmes de délivrance de médicaments / Tocophérols / Nanoparticules / Irinotécan / Antinéoplasiques Limites: Animals / Humans Langue: En Journal: Clin Cancer Res Sujet du journal: NEOPLASIAS Année: 2018 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Promédicaments / Systèmes de délivrance de médicaments / Tocophérols / Nanoparticules / Irinotécan / Antinéoplasiques Limites: Animals / Humans Langue: En Journal: Clin Cancer Res Sujet du journal: NEOPLASIAS Année: 2018 Type de document: Article